6Y4 Stock Overview
A clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Vicore Pharma Holding AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 0.72 |
52 Week High | SEK 2.01 |
52 Week Low | SEK 0.56 |
Beta | 0.66 |
1 Month Change | 19.05% |
3 Month Change | 18.66% |
1 Year Change | -42.09% |
3 Year Change | -55.47% |
5 Year Change | n/a |
Change since IPO | -58.33% |
Recent News & Updates
Recent updates
Shareholder Returns
6Y4 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 8.9% | 4.0% | 0.7% |
1Y | -42.1% | -10.2% | 8.4% |
Return vs Industry: 6Y4 underperformed the German Biotechs industry which returned -11.7% over the past year.
Return vs Market: 6Y4 underperformed the German Market which returned 8.4% over the past year.
Price Volatility
6Y4 volatility | |
---|---|
6Y4 Average Weekly Movement | 7.8% |
Biotechs Industry Average Movement | 7.3% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 12.0% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6Y4's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 6Y4's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 29 | Ahmed Mousa | www.vicorepharma.com |
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases. It develops C21, an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. The company is also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis.
Vicore Pharma Holding AB (publ) Fundamentals Summary
6Y4 fundamental statistics | |
---|---|
Market cap | €189.92m |
Earnings (TTM) | -€17.16m |
Revenue (TTM) | €9.10m |
20.9x
P/S Ratio-11.1x
P/E RatioIs 6Y4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6Y4 income statement (TTM) | |
---|---|
Revenue | SEK 104.24m |
Cost of Revenue | SEK 0 |
Gross Profit | SEK 104.24m |
Other Expenses | SEK 300.69m |
Earnings | -SEK 196.45m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 27, 2025
Earnings per share (EPS) | -0.84 |
Gross Margin | 100.00% |
Net Profit Margin | -188.45% |
Debt/Equity Ratio | 0% |
How did 6Y4 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/02 10:55 |
End of Day Share Price | 2025/01/02 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vicore Pharma Holding AB (publ) is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Hanseung Yoo | Bryan Garnier & Co |
Oscar Haffen Lamm | Bryan Garnier & Co |
Patrik Ling | DNB Markets |